INVO Bioscience

IINVO BioScience, Inc. is a fertility company. It focuses on the creation of treatment options for patients diagnosed with infertility. It offers a patented medical device that is used for infertility treatment under the name INVOcell. The company was founded by Kathleen Karloff and Claude Ranoux on January 5, 2007 and is headquartered in Sarasota, FL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NAYA Biosciences, Inc. operates a revenue-generating fertility business. It also focuses on the development of class clinical-stage assets in oncology and autoimmune diseases. The company was founded on October 14, 2024 and is headquartered in Sarasota, FL.

SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility, today announced an update regarding its clinic trial plans. The Company received regulatory approval from the Israeli Ministry of Health in July 2024 and subsequent institutional review board clearance to initiate patient enrollment in up to 7 academic centers for its clinical trial evaluating the safety and efficacy of NY-303, its GPC3-targeting NK Engager bispecific antibody, as a monotherapy for the treatment of hepatocellular carcinoma in patients not responding to first-line immunotherapy.

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

SARASOTA, Fla. and MIAMI, Oct. 21, 2024 (GLOBE NEWSWIRE) -- INVO Biosciences (Nasdaq: INVO), a company focused on expanding its portfolio of clinical and commercial-stage assets in fertility, oncology, and autoimmune diseases through the merger of INVO Biosciences and NAYA Biosciences, today confirmed it has changed its corporate name to NAYA Biosciences Inc. and will begin trading under the new symbol “NAYA” at the market open on Tuesday, October 22, 2024.

INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences

Combined company to expand portfolio of clinical & commercial-stage assets in fertility, oncology, and autoimmune diseases Combined company to expand portfolio of clinical & commercial-stage assets in fertility, oncology, and autoimmune diseases

INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)

SARASOTA, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the first quarter of 2024 and provided a business update.

INVO Reports Record First Quarter 2024 Financial Results

Invo Bioscience (NASDAQ: INVO ) stock is rocketing higher on Wednesday alongside its earnings report for the fourth quarter of 2023. The healthcare services fertility company reported a net loss of $2 million during the quarter.

Why Is Invo Bioscience (INVO) Stock Up 85% Today?

SARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.

INVO Reports Fourth Quarter and Full Year 2023 Financial Results

Abstract from 2023 American Society of Hematology (ASH) Meeting Data demonstrates differentiated profile from DARZALEX® (daratumumab) with best-in-class potential, supports initiation of clinical trials in 2024 NAYA expects to close its previously announced merger with INVO Bioscience (NASDAQ: INVO) in the first quarter of 2024 AVENTURA, Fla. and SARASOTA, Fla.

NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal

NAYA Biosciences and ONK Therapeutics to assess proof-of-concept and establish activity and feasibility of the combination of NAYA's FLEX-NK™ bispecific antibodies and ONK's optimally engineered natural killer (NK) cells for the treatment of cancer Partnership may be expanded to joint clinical development following successful completion of the initial research Combination therapy expected to improve response rate and address significant unmet medical need in hepatocellular carcinoma (HCC) NAYA expects to close its previously announced merger with INVO Bioscience (NASDAQ:  INVO) in the first quarter of 2024 AVENTURA, Fla. and SARASOTA, Fla.

NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies

SARASOTA, Fla. , Nov. 28, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced the Company received notice from The Nasdaq Capital Market, LLC ("Nasdaq"), dated November 22, 2023, informing INVO that it has regained compliance with the minimum stockholders' equity requirement as set forth under NASDAQ Listing Rule 5550(b)(1) for continued listing on Nasdaq.

INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Company Expects to Host Conference Call Shortly After November 20, 2023 Following the Progress of Certain Closing Conditions Pertaining to the Announced Merger Agreement with NAYA Biosciences SARASOTA, Fla. , Nov. 13, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the third quarter ended September 30, 2023 and provided a business update.

INVO Reports Record Third Quarter 2023 Financial Results

NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger

SARASOTA, Fla. , Nov. 9, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, announced that it is soliciting waivers (the "Waiver Solicitation") from holders of the Company's common stock purchase warrants dated August 8, 2023 (the "Warrants") of the holder's right to exercise a cash payment option upon consummation of the previously announced proposed merger with NAYA Biosciences, Inc., a Delaware corporation ("NAYA").

INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase Warrants

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of INVO Bioscience, Inc. (the “Company”) (NasdaqCM: INVO) with NAYA Biosciences Inc. Under the terms of the proposed transaction, (subject to the Interim PIPE, post-transaction and prior to the private offering), INVO shareholders will own approximately 12% of the combined company. KSF is seeking to determine w.

INVO BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of INVO Bioscience, Inc. - INVO

MILWAUKEE , Oct. 23, 2023 /PRNewswire/ -- Ademi LLP is investigating INVO (Nasdaq: INVO) for possible breaches of fiduciary duty and other violations of law in its transaction with NAYA Biosciences. Click here to learn how to join the action https://www.ademilaw.com/case/invo-bioscience-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether INVO Bioscience, Inc. has obtained a Fair Price in its transaction with NAYA Biosciences

One of the most impressive movers making the most noise in today's session has to be INVO Bioscience (NASDAQ: INVO ). Shares of INVO stock have more than tripled in today's session, surging well more than 325% at the time of writing.

Why Is INVO Bioscience (INVO) Stock Up 325% Today?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of INVO Bioscience, Inc. (NASDAQ: INVO) and NAYA Biosciences Inc. is fair to INVO shareholders. Halper Sadeh encourages INVO shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether INVO and its board violated the federa.

INVO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of INVO Bioscience, Inc. Is Fair to Shareholders

Post-merger, the combined company, operating under the name "NAYA Biosciences", will be dedicated to increasing patient access to life-transforming treatments in oncology, fertility, and regenerative medicine NAYA will seek to scale up profitable revenues in the fertility segment, enter into revenue-generating pharma partnerships for its therapeutic programs, and strategically develop and acquire synergistic technologies and companies SARASOTA, Fla. and AVENTURA, Fla.

INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company

SARASOTA, Fla. , Oct. 11, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, announced today that Steve Shum, CEO, will be participating in a Panel Presentation at the Lytham Partners Fall 2023 Investor Conference on Tuesday, October 17, 2023.

INVO to Participate in the Lytham Partners Fall 2023 Investor Conference

SARASOTA, Fla. , Sept. 29, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company") today announced that its special meeting of shareholders on September 29, 2023 (the "Special Meeting") was convened and then adjourned, without conducting any business, in order to provide shareholders additional time within which to vote on the proposals as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 1, 2023 (the "Proxy Statement").

INVO BIOSCIENCE ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF SHAREHOLDERS

SARASOTA, Fla. , Sept. 28, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, reminds its shareholders to vote ahead of the upcoming special meeting of shareholders (the "Special Meeting") to be held on September 29, 2023 at 12:00 pm (Eastern time).

INVO Reminds Shareholders to Cast Their Vote for Upcoming Special Meeting of Shareholders to be held on Friday, September 29, 2023 at 12:00 p.m. ET

INVO Bioscience, Inc. (NASDAQ:INVO ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Robert Blum - Investor Relations Steve Shum - Chief Executive Officer Mike Campbell - Chief Operating and Vice President, Business Development Andrea Goren - Chief Financial Officer Operator Good afternoon. And welcome, to the INVO Bioscience Second Quarter Fiscal Year 2023 Financial Results Conference Call.

INVO Bioscience, Inc. (INVO) Q2 2023 Earnings Call Transcript

Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla. , Aug. 14, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the second quarter ended June 30, 2023 and provided a business update.

INVO Reports Second Quarter 2023 Financial Results

Transformational and accretive acquisition adds significant scale to INVO's current operations Contributes over $5 million in incremental annual revenue as well as positive net income and cash flows First significant transaction establishing acquisitions as key aspect of INVO's commercial strategy, in addition to building new INVO Centers SARASOTA, Fla. and MADISON, Wis.

INVO Closes Acquisition of Wisconsin Fertility Institute

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , Aug. 9, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its second quarter 2023, for the period ended June 30, 2023, after the market close on Monday, August 14, 2023.

INVO to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

SARASOTA, Fla. , Aug. 8, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced the closing of its public offering of 1,580,000 units, with each unit consisting of one share of common stock and two warrants, each to purchase one share of common stock.

News for INVO Bioscience Stock (INVO)